Skip to content

Investors Overview

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated  low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.  Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-friendly, and payer-friendly”.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.



Esperion Therapeutics (NASDAQ: ESPR) 3:03 PM ET on Sep 21, 2017
Last Price 49.20 Change -0.48(-0.956%) open 49.76 Day High 49.83 52-Week High 57.38
Volume 152,863 Previous Close 49.67 Day Low 48.85 52-Week Low 9.40

Press Releases

Load More